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BSE = breast self-examination; DCIS = ductal carcinoma in situ; HIP = Health Insurance Plan; MP = mammography plus physical examination;
NBSS = National Breast Screening Study; PO = physical examination alone.
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Abstract
Data from randomised controlled trials of mammographic screening
can be used to determine the extent of any overdiagnosis, as soon
as either a time equivalent to the lead-time has elapsed after the
final screen, or the control arm has been offered screening. This
paper reviews those randomised trials for which breast cancer
incidence data are available. In recent trials in which the control
group has not been offered screening, an excess incidence of
breast cancer remains after many years of follow-up. In those trials
in which the control arm has been offered screening, although there
is a possible shift from invasive to in situ disease, there is no
evidence of overdiagnosis as a result of incident screens.
Introduction
Overdiagnosis in mammographic screening is taken here to
mean the diagnosis of invasive or in situ breast cancer that, in
the absence of screening, would not have presented clinically
during the woman’s lifetime.
In studying overdiagnosis, randomised controlled trials have
the advantage that data on the incidence of breast cancer in
the intervention and control arms are usually available in detail
at an individual level. Overdiagnosis of both ductal carcinoma
in situ (DCIS) and invasive cancer may occur; however, it is
not easy to determine to what extent an excess of DCIS is
due to stage-shifting from invasive disease, although
estimates can be made where sufficiently detailed information
is available [1]. Most trials have provided relatively little
information on the treatment of breast cancer cases, so that
the extent of overtreatment is difficult to quantify.
Overdiagnosis can be studied in randomised controlled trials
by comparing the cumulative incidence of breast cancer in
the intervention and control arms at different times from date
of entry or randomisation. While screening is continuing in
the intervention arm of a trial, incidence in that arm will be
increased because of the advancement of diagnosis by the
lead-time in screen-detected cancers, as well as by any
overdiagnosis. This ‘prevalence peak’ will be followed by a
corresponding decrease once screening ceases. Over-
diagnosis can therefore be estimated only after a time
equivalent to the lead-time has elapsed following the final
screen. In several trials, women in the control arm have
subsequently been offered screening. Once this has
occurred, only overdiagnosis due to incident, not prevalent,
screens would be observable, because women in both arms
of the trial would be subject to any overdiagnosis occurring at
prevalent screens.
The extent of any overdiagnosis in trials of breast screening
may be affected by the ‘intensity’ of screening (one or two
views, modalities employed, screening frequency and recall
policy), and by the uptake of screening in the intervention
arm. It may also depend on the age range of women included
in the trial, both because of variation in the natural history of
the disease with age and because of increased mortality from
other causes in older women during the ‘lead-time’ before a
screen-detected cancer would have presented clinically. The
extent to which overdiagnosis is observed will also depend
on the extent of ‘contamination’ in the control arm by
opportunistic screening.
Method
This review considers those randomised trials that include
screening by mammography (with or without clinical
examination). There are eight randomised controlled trials of
mammography that have so far completed and reported
mortality results, and for which data on breast cancer
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incidence are available [2]. The main characteristics of these
trials are described in Table 1.
Data have been abstracted from published reports on the
cumulative incidence of breast cancer in intervention and
control arms in each trial; where available, data have been
abstracted for a period of follow-up extending sufficiently
beyond the final screen to allow for lead-time, or after women
in the control arm have been invited for screening. The
absolute excess per 1,000 women years in the intervention
arm compared with the control arms is presented in Table 2
for invasive breast cancers, for DCIS, and for invasive
cancers and DCIS combined, together with 95% confidence
intervals for the absolute excess. The ratio of the incidence
rate of all breast cancers in the intervention arm to that in the
control arm is shown in Fig. 1.
For studies in which rates have been published only per
1,000 women, rates per 1,000 women years have been
calculated on the basis of estimated mean follow-up.
The randomised trials
The earliest of the randomised trials was the Health Insurance
Plan (HIP) study performed in the United States in the 1960s,
in which women in the intervention arm were offered annual
screening by both mammography and clinical breast
examination for four rounds. By the end of 5 years from date
of entry (about 1.5 years after the last screen) the incidence
of breast cancer in the two arms was similar (2.03 per 1,000
women years in the intervention arm, and 1.94 in the control
arm [3]). An earlier report indicates that the percentages of in
situ cancer were 13% and 8%, respectively, in the two arms
[4]. There have been considerable improvements in the
sensitivity of mammography since this trial was conducted,
and it therefore provides little indication of the potential for
overdiagnosis with current techniques.
The four randomised trials conducted in Sweden all used
screening by mammography alone, with screening intervals
ranging from 18 to 33 months. In all except one of these the
control group has subsequently been offered screening.
The Swedish Two County Study, which began in 1977/8,
included 143,867 women aged 40 to 74 years at the date of
randomisation [5]. Women in the intervention arm were
invited to screening at intervals of 24 to 33 months.
In 1985, after two to four rounds of screening in the
intervention arm, women in the control arm were offered
screening. After this screen had taken place, rates of invasive
cancer have been reported as 16.90 and 17.79 per 1,000
women in the intervention and control arms, respectively;
assuming an average of 7 years of follow-up, the estimated
rates per 1,000 women years are 2.41 and 2.54,
respectively, with rates of DCIS of 0.23 and 0.12 per 1,000
women years, respectively [6].
The Gothenberg trial invited women aged between 35 and
59 years, between 1982 and 1991. Again, women in the
control arm were offered a single screen at approximately the
same time as the final screen in the intervention arm.
The cumulative incidence of invasive breast cancer was greater
in the intervention arm than in the control arm until year 6, at
about the time of the first screen in the control arm. At the end
of the ‘screening phase’ of the trial (that is, the period up to and
including the first screen in the control arm), rates of DCIS were
slightly higher in the intervention arm (about 0.22 versus 0.17
Table 1
Randomised controlled trials of mammographic screening
Age range  Screening  Uptake  Relative risk 
at entry  interval  Number rate (%)  of breast  Follow-up 
Study (years) (months) of views (prevalent screen) cancer mortality (years)
HIP 40–64 12 2 67 0.78 18
Two County 40–74 24–33 1 89 0.70 11
Malmö I 45–70 18–24 2 74 0.81 19
Malmö II 43–49 18–24 2 75–80 0.65 9
Stockholm 40–64 28 1 81 0.90 15
Goteborg 39–59 18 2 84 0.78 13
NBSS Ia 40–49 12 2 100 1.06 13
NBSS IIb 50–59 12 2 100 1.02 13
Edinburgh 45–64 12c 2 61 0.78 13
aComparison of annual mammography, clinical breast examination (CBE) and breast self-examination (BSE) instruction with a single CBE and BSE
instruction. bComparison of annual mammography with annual CBE. cMammography and CBE every 24 months; CBE only in intervening years.
HIP, Health Insurance Plan; NBSS, National Breast Screening Study.232
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per 1,000 women years), with a slightly lower rate of invasive
cancers (1.56 versus 1.73 per 1,000 women years) [7]. The
relative risk of overall breast cancer incidence in the intervention
arm relative to the control arm at follow-up of up to 14 years is
reported as 0.98 (95% confidence interval 0.88 to 1.09).
The first Malmö trial invited women between 45 and 69 years
old to five rounds of screening between 1976 and 1978.
Women in the control arm were not invited for screening
(although those in the youngest cohort were eventually
invited in 1992/3). At a mean follow-up of 8.8 years, when
screening was still continuing, the rates of invasive breast
cancers in the intervention and control arms were 2.62 and
2.12 per 1,000 women years, respectively. The rates of DCIS
were 0.50 and 0.27 per 1,000 women years, respectively [8].
It was estimated that 24% of the control arm had been
screened, although most only once. No incidence data have
been published on the subsequent (Malmö II) trial.
The Stockholm trial randomised about 60,000 women in
1981; there were two screening rounds using single-view
mammography 28 months apart; during 1986 the control
group was invited to a single screen. Uptake at first screen
was 81% in the intervention arm and 77% in the control arm
[9]. At the end of 1986 there was no difference in overall
cancer incidence between the two arms (0.90 versus 0.91
per 1,000 women years). There was a slightly higher rate of
DCIS (0.09 versus 0.06) and lower rate of invasive cancers
(0.81 versus 0.85) in the intervention arm, but the differences
were not significant.
Two trials conducted in Canada both used volunteer
populations, resulting in high uptake. The NBSS II trial was
designed to compare mammography plus physical
examination (MP), with physical examination alone (PO) in
women aged 50 to 64 years [10]. An initial excess of invasive
cancers in the MP arm mainly disappeared with continued
follow-up; at 13 years of follow-up, rates per 1,000 women
years were 2.43 and 2.38 in the MP and PO arms,
respectively [11]. Rates of DCIS were 0.28 and 0.06 per
1,000 women years, respectively. The NBSS I trial was
designed to compare breast cancer mortality in women aged
40 to 49 years randomised to either screening by annual
mammography, physical examination and instruction on breast
self-examination (BSE) or a single physical examination and
BSE instruction [12]. After 13 years of follow-up, the
cumulative rates of DCIS were 0.22 and 0.09 per 1,000
women years in the screening and ‘usual care’ groups,
respectively [13]. The rates of invasive breast cancers were
1.81 and 1.68, respectively, per 1,000 women years.
The Edinburgh trial recruited women aged 45 to 64 years into
the initial cohort during 1978 to 1981, with randomisation by
general practice. Women in the intervention arm were offered
annual screening for 7 years, by mammography and physical
examination every 2 years, and physical examination only in
the intervening years. At 10 years of follow-up the incidence
rates of invasive breast cancer were 2.04 and 1.93 per 1,000
women years in the intervention and control arms,
respectively; rates of DCIS were 0.19 and 0.05, respectively,
per 1,000 women years [14].
Table 2
Randomised controlled trials of mammography screening: differences in breast cancer incidence between intervention and control
arms in the follow-up period
Cumulative incidence of  Cumulative incidence of  Cumulative incidence of 
invasive breast cancer  DCIS  all breast cancer (invasive + DCIS) 
(per 1,000 women years) (per 1,000 women years) (per 1,000 women years)
Absolute Absolute Absolute 
excess in  excess in  excess in  Follow- Control 
Control intervention  95%  Control intervention  95%  Control intervention  95%  up  group 
Study group arm Cl group arm Cl group arm Cl (years) screened
Two County 2.54 –0.13a –0.29, 0.04 0.12 0.11 0.07, 0.15 2.66 –0.02 –0.19, 0.15 11 Yes
Stockholm 0.85 –0.04 –0.18, 0.10 0.06 0.03 –0.00, 0.07 0.91 –0.03 0.15, 0.14 5 Yes
Goteberg 1.73 –0.17 –0.42, 0.08 0.17 0.05 –0.03, 0.14 1.90 –0.11 –0.38, 0.15 8 Yes
HIP 1.94 0.09a –0.24, 0.39 No data No data No data 1.94 0.07 –0.24, 0.39 5 No
Malmö I 2.12 0.50 0.18, 0.81 0.27 0.23 0.11, 0.36 2.39 0.73 0.39, 1.07 8.8 No
NBSS I 1.68 0.12  –0.08, 0.32 0.09 0.13 0.07, 0.18 1.77 0.25 0.04, 0.46 13 No
NBSS II 2.38 0.04  –0.22, 0.31 0.06 0.21 0.14, 0.28 2.44 0.26 –0.02, 0.54 13 No
Edinburgh 1.93 0.11  –0.15, +0.38 0.05 0.13 0.07, 0.20 1.98 0.25 –0.00, 0.53 10 No
aAll breast cancers. CI, confidence interval; DCIS, ductal carcinoma in situ; HIP, Health Insurance Plan; NBSS, National Breast Screening Study.233
However, the cluster randomisation in this trial led to an
imbalance in socio-economic status, reflected in all-cause
mortality, which is likely to have resulted in an increased risk
of breast cancer in the intervention arm. Adjustment for this
altered the rate ratio of breast cancer mortality at 14 years of
follow-up from 0.87 to 0.79 [15].
Summary of the trials
In Table 2 the trials are grouped according to whether the
control group had been offered screening. For the three trials
in which this occurred the absolute excess of all breast
cancers in the intervention arm ranged from –0.02 to –0.11
per 1,000 women years; the ratio of the incidence in the
intervention arm to that in the control arm was 0.94 to 0.99.
For DCIS the absolute excess ranged from 0.05 to 0.11, and
for invasive cancer from –0.84 to –0.17.
By contrast, in those trials in which the control group had not
been offered screening, there was an excess of both invasive
cancers and DCIS in the intervention arm, although in the
Malmö trial screening was still in progress at the time that
rates were reported. The two Canadian trials are the most
informative because they were conducted most recently and
have 13 years of follow-up; these show an absolute excess of
all breast cancers of 0.25 to 0.26 per 1,000 women years;
the ratio of the incidence in the intervention arm to that in the
control arm was 1.11 to 1.14.
UK trials of age and frequency
Two further trials in the UK have not yet reported mortality
results. The ‘age’ trial is offering annual mammography from
the age of 40 or 41 years to an intervention arm [16]; women
in both arms will be invited as part of the national programme
at ages 50 to 52 years. At the time of an interim analysis,
when screening was still in progress, there was an 8%
excess diagnosis of invasive breast cancers and a 17%
excess of all breast cancers in the intervention arm in
comparison with the control arm [17]. Once all women in
both arms have been invited for screening in the national
programme, any excess diagnosis should be as a result of
incident screens.
The ‘frequency’ trial has compared annual versus three-yearly
screening in women aged 50 to 64 years within the UK
National Health Service breast screening programme [18].
Because all women had received a prevalent screen before
randomisation, any excess diagnosis should be the result of
more frequent screening (or difference in uptake). At 3 years
of follow-up (that is, when both arms had been reinvited) a
non-significant increase in breast cancers of 19% (13%
invasive) was observed in the annual screening arm. Although
the authors did not consider the difference to be real, they
acknowledged a possible effect of increased diagnostic
activity. The (31%) increase in DCIS was also non-significant.
Conclusion
This paper summarises the evidence for overdiagnosis in
randomised trials of mammography, on the basis of
comparisons of cumulative incidence, in the intervention and
control arms of such trials. It is noted that differences in
breast cancer incidence can also arise from bias in
randomisation, and indeed equality of incidence has been
used as evidence for a lack of such bias [7]. No mathematical
modelling of the extent of overdiagnosis has been attempted
in the present paper, because this will be the subject of a
later paper in this series.
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Figure 1
Relative incidence of all breast cancers; ratios of intervention arm to
control arm. (a) Randomised controlled trials with screening in the
control arm. (b) Randomised controlled trials without screening in the
control arm. HIP, Health Insurance Plan; NBSS, National Breast
Screening Study.
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In trials in which the control group has not been offered
screening, only once sufficient time has elapsed since the
end of screening can overdiagnosis be estimated. If
screening in the intervention arm is still continuing at the time
incidence is reported, an increase in the intervention arm
would be expected owing to advanced diagnosis, as
observed in the Malmö trials. In the Canadian trials there is an
11 to 14% excess of all cancers in the intervention arm at
13 years of follow-up, largely of DCIS, suggesting the
existence of overdiagnosis. However, in those recent trials in
which the control group have been invited for screening,
although there is a possible shift from invasive disease to
DCIS, there is no evidence of overdiagnosis of all breast
cancers as a result of incident screens.
Competing interests
The author(s) declare that they have no competing interests.
References
1. Yen MF, Tabar L, Vitak B, Smith RA, Chen HH, Duffy SW: Quan-
tifying the potential problem of overdiagnosis of ductal carci-
noma in situ in breast cancer screening. Eur J Cancer 2003,
39:1746-1754.
2. Vainio H, Bianchini F: Breast Cancer Screening: IARC Hand-
books of Cancer Prevention. Lyon: IARC Press; 2002.
3. Shapiro S, Venet W, Strax P, Venet L, Roeser R: Ten- to four-
teen-year effect of screening on breast cancer mortality. J Natl
Cancer Inst 1982, 69:349-355.
4. Shapiro S: Evidence on screening for breast cancer from a
randomized trial. Cancer 1977, 39:2772-2782.
5. Tabar L, Fagerberg CJ, Gad A, Baldetorp L, Holmberg LH,
Grontoft O, Ljunquist U, Lundstrom B, Manson JC, Eklund G, et
al.:  Reduction in mortality from breast cancer after mass
screening with mammography. Randomised trial from the
Breast Cancer Screening Working Group of the Swedish
National Board of Health & Welfare. Lancet 1985, i:829-832.
6. Duffy SW, Tabar L, Vitak B, Day NE, Smith RA, Chen HHT, Yen
MFA: The relative contributions of screen-detected insitu and
invasive breast carcinomas in reducing mortality from the
disease. Eur J Cancer 2003, 39:1755-1760.
7. Bjurstam N, Bjorneld L, Warwick J, Sala E, Duffy SW, Nystrom L,
Walker N, Cahlin E, Eriksson O, Hafstrom LO, et al.: The Gothen-
burg Breast Screening Trial. Cancer 2003, 97:2387-2396.
8. Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell
F, Ljungberg O, Ranstam J, Sigfusson B: Mammographic
screening and mortality from breast cancer: the Malmö mam-
mographic screening trial. BMJ 1988, 297:943-948.
9. Frisell J, Lidbrink E, Hellstrom L, Rutqvist L-E: Follow up after 11
years – update of mortality results in the Stockholm mammo-
graphic screening trial. Breast Cancer Res Treat 1997, 45:263-
270.
10. Miller AB, Baines CJ, To T, Wall C: Canadian National Breast
Screening Study: 2. Breast cancer detection and death rates
among women aged 50 to 59 years. Can Med Assoc J 1992,
147:1477-1488.
11. Miller AB, To T, Baines CJ, Wall C: Canadian National Breast
Screening Study – 2: 13-year results of a randomized trial in
women aged 50–59 years. J Natl Cancer Inst 2000, 92:1490-
1499.
12. Miller AB, Baines CJ, To T, Wall C: Canadian National Breast
Screening Study: 1. Breast cancer detection and death rates
among women aged 40 to 49 years. Can Med Assoc J 1992,
147:1459-1476.
13. Miller AB, To T, Baines CJ, Wall C: The Canadian National
Breast Screening Study – 1: Breast cancer mortality after 11 to
16 years of follow-up. Ann Intern Med 2002, 137:E-305-E-315.
14. Alexander FE, Anderson TJ, Brown HK, Forrest AP, Hepburn W, Kirk-
patrick AE, McDonald C, Muir BB, Prescott RJ, Shepherd SM: The
Edinburgh randomised trial of breast cancer screening: results
after 10 years of follow-up. Br J Cancer 1994, 70:542-548.
15. Alexander FE, Anderson TJ, Brown HK, Forrest APM, Hepburn W,
Kirkpatrick AE, Muir BB, Prescott RJ, Smith A: 14 years of
follow-up from the Edinburgh randomised trial of breast-
cancer screening. Lancet 1999, 353:1903-1908.
16. Moss S: A trial to study the effect on breast cancer mortality of
annual mammographic screening in women starting at age
40. Trial Steering Group. J Med Screen 1999, 6:144-148.
17. Moss S, Waller M, Anderson TJ, Cuckle H (writing committee for
the Trial Management Group): Randomised controlled trial of
mammographic screening in women from age 40: predicted
mortality based on surrogate outcome measures. Br J Cancer
2005, 92:955-960.
18. The Breast Screening Frequency Trial Group: The frequency of
breast cancer screening: results from the UKCCCR Ran-
domised Trial. Eur J Cancer 2002, 38:1458-1464.
Breast Cancer Research    October 2005 Vol 7 No 5 Moss